GILD250117P80000
- 0.01
- -0.01-50.00%
Gilead Sciences Newsroom
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating
Gilead Sciences Analyst Ratings
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Gilead Sciences' Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $99 to $115
Gilead Sciences Price Target Maintained With a $80.00/Share by Cantor Fitzgerald
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Receives a Buy From Jefferies
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $105 to $125
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating